TADCLOT- a Double Blind Randomized Controlled Trial
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2200 participants.
Also called NCT06318481
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,200 participants
- Registry
-
NCT06318481
-
- Other papers using this trial's data
- Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Pakistan
- Registry status
- Completed
Technical summary
Registry record NCT06318481. Randomized; triple masking; primary purpose treatment. Start 2024-02-19 (actual); primary completion 2025-02-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- TADCLOT- a Double Blind Randomized Controlled Trial
- Acronym
- TADCLOT
- Condition
- Stent Thrombosis
- Condition
- Myocardial Infarction, Acute
- Intervention (Drug)
- Ticagrelor 90 MG
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- National Institute of Cardiovascular Diseases, Pakistan
- Collaborator
- PharmEvo Pvt Ltd
Record details
- Record id
cardio:ct-nct06318481- Content hash
a50c4adb02b9da2dd317582dcaae45596bb8ef55e7e121e36ff1db8a9878f843